Gilead’s Lenacapavir License: Limitations and Access Recommendations

Gilead's voluntary license for lenacapavir limits access, restricting generic manufacturing and distribution. MSF urges Gilead to expand licensing terms to improve global access, especially in resource-limited settings, amid urgent HIV prevention needs highlighted by 1.3 million new infections.